Licensing Opportunities

Opportunity TitleDescriptionRead More
Anticancer antibody targeting NPY & PYY A humanised monoclonal antibody functioning via a novel mechanism of action that effectively neutralizes NPY/PYY, reducing tumour growth and increasing survival in animal tumour models. The antibody has a dual effect; directly targeting the tumour in addition to modulation of the immune system. Read more – View or download the flyer

Antibody Stabilisation Technology

A novel platform technology which overcomes instability and aggregation problems encountered with human therapeutic antibodies rapidly and without sacrificing affinity. Key benefits include increased manufacturing yields, increased formulation concentrations and increased stability towards freeze-thawing and other manufacturing processes. Mutations can be retrofitted into existing antibodies to optimize formulation and allow new delivery applications. Read more – View or download the flyer
New target for insulin resistance & Type-2 Diabetes: PKCε The lipid-regulated protein kinase C isoform, PKCε, plays a central role in β-cell dysfunction. Inhibition of PKCε corrects multiple dysfunctions associated with type-2 diabetes - including increasing glucose stimulated insulin secretion - with minimal side effects, providing unique benefits over existing therapies.  Read more – View or download the flyer
Inhibition of Id1 – a new treatment for Type-2 Diabetes Id1 (Inhibitor of DNA binding) is a member of a family of proteins that inhibit cell differentiation. While its expression is normally suppressed in healthy adult cells, it is progressively upregulated in human β-cells as type- 2 diabetes develops.  Inhibition of Id1 in pancreatic β-cells has been shown to increase glucose-stimulated insulin secretion. Read more – View or download the flyer
Novel marker for diagnosis of ovarian cancer A novel diagnostic biomarker for the detection of ovarian cancer.  Hyper-methylation of LOC134466 - indicative of the presence of cancer and measurable in blood measured – is candidate marker for early detection and post-surgical surveillance or monitoring the success of treatment and relapse/recurrence of disease. Read more – View or download the flyer